Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly And Company's (NYSE:LLY) weight-loss drug, Zepbound (tirzepatide), is gaining traction in the U.S., rivaling Novo Nordisk A/S's (NYSE:NVO) Wegovy (semaglutide).
伊利莎白·利利公司（NYSE:LLY）的减肥药Zepbound（地塞帕肽）在美国越来越受欢迎，与诺和诺德A/S（NYSE:NVO）的Wegovy（塞格列汀）相媲美。
Due to ongoing supply issues, some doctors are prioritizing availability when prescribing these medications.
由于持续供应问题，一些医生在开处方药时会优先考虑药物的可用性。
Also Read: Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks.
此外，使用Wegovy、Zepbound等减肥药物的心理学家警告存在与进食障碍风险相关的问题。
Reuters noted, citing IQVIA data, that Eli Lilly has captured roughly 40% of the market since Zepbound's December launch.
据IQVIA数据称，自Zepbound在12月上市以来，伊利莎白·利利公司已经占据了约40%的市场。
As of July 19, 130,000 prescriptions were filled weekly, compared to 200,000 for Wegovy.
截至7月19日，每周约填写130,000份处方，而Wegovy为200,000份。
Five U.S. obesity specialists revealed they prescribe whichever drug is more accessible, sometimes requiring patients to switch treatments to maintain continuity.
五位美国肥胖症专家透露，他们会开具更容易拿到的药物，有时需要患者更换药物以保持疗效。
Investors are keenly awaiting updates from Novo Nordisk and Lilly during their quarterly earnings release this week.
投资者将密切关注诺和诺德和利莲公司在本周季度财务会议的更新。
"All doses of Mounjaro and Zepbound are listed as available on the FDA's website, consistent with our previous statements that supply would steadily improve toward the latter half of 2024," Reuters added, quoting an Eli Lilly spokesperson.
路透社援引伊利莎白·利利公司的发言人表示："Mounjaro和Zepbound的所有剂量均已列入FDA网站，这与我们之前的声明一致，即供应将稳步提高，直至2024年下半年。"
"While we will do our best to support those who want to start taking Wegovy, it is important to recognize that overall demand will continue to exceed supply, and some patients may still have difficulty filling Wegovy prescriptions," Novo Nordisk noted in an update on its website.
诺和诺德在其网站上更新说："尽管我们会尽最大努力支持那些想开始使用Wegovy的患者，但有必要认识到总体需求仍将超过供应，一些患者可能仍难以获得Wegovy处方。"
Meanwhile, Lilly's CEO recently assured that the Zepbound shortage would be resolved "very soon." The FDA updated its status on Friday, indicating that while Zepbound is available, it remains on the shortage list pending confirmation of stable supplies.
与此同时，利莲公司的CEO最近保证，Zepbound的药短缺问题将"很快"解决。FDA上周五更新了其状态，说明虽然Zepbound可用，但其仍在短缺清单上，需要确认稳定的供应。
The FDA's website still lists shortages for the lowest three out of five dose strengths of Wegovy. Since Q2, Novo Nordisk has averaged nearly 170,000 weekly U.S. prescriptions for Wegovy, while Lilly has filled just under 100,000.
FDA网站仍然列出Wegovy五个剂型中最低的三个剂量存在短缺。自第二季度以来，诺和诺德在美国的Wegovy处方量平均每周近170,000张，而利莲公司仅填写了将近100,000张。
Analysts predict a roughly even market split by the end of 2024 as Lilly boosts its manufacturing capacity.
分析师预计到2024年底，市场份额将基本相当，因为利莲公司将增加其制造能力。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases.
- FDA小组支持Zevra的Arimoclomol治疗罕见遗传性疾病，分析师强调其平衡的市场产品组合和侧重于罕见疾病的管道资产。
Photo by Ciara Kimsey via Shutterstock
照片来自Shutterstock